Subcutaneous PT-141 (bremelanotide) safely induced erections in ED patients in a double-blind RCT, with dose-dependent efficacy and pharmacokinetics supporting SC delivery as a practical clinical route.
Key findingSC PT-141 induced dose-dependent erectile responses in ED patients (double-blind, placebo-controlled) with characterized pharmacokinetics, acceptable
What the researchers found
SC PT-141 induced dose-dependent erectile responses in ED patients (double-blind, placebo-controlled) with characterized pharmacokinetics, acceptable safety, and practical SC delivery — advancing toward clinical approval.
Why it matters
Relevant for pt-141, sexual-health, clinical-trials, bioavailability.
How the study worked
RCT study on pt-141, sexual-health.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2004.
The bigger picture
Advances peptide therapeutics research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.
International journal of impotence research, 16(2), 135-42
Citation
Rosen, R C; Diamond, L E; Earle, D C; Shadiack, A M; Molinoff, P B. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.. International journal of impotence research, 16(2), 135-42.